By Sabela Ojea

 

Shares of Autolus Therapeutics Ltd. on Tuesday rose 14% after the U.K. leukemia drug maker announced the signing of collaboration agreement for the treatment of cancer with pharmaceutical company Bristol Myers Squibb Co.

In premarket trading, the stock was up $2.49 after it closed at $2.18 Monday. The shares have fallen more than 50% so far this year.

The biopharmaceutical will receive an upfront payment from Bristol Myers, with the potential to exercise option fees, development milestone payments and royalties, the company said without disclosing details.

Through the agreement, Autolus said it will grant Bristol Myers access to its Rituximab Safety Switch RQR8 to develop a selection of cell therapy programs for the treatment of cancer.

Bristol Myers will have the option to incorporate the RQR8 safety switch in additional cell therapy programs beyond the initial set of selected programs, the company said.

 

Write to Sabela Ojea at sabela.ojea@wsj.com

 

(END) Dow Jones Newswires

October 04, 2022 08:02 ET (12:02 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Autolus Therapeutics Charts.
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Autolus Therapeutics Charts.